Selected gastrointestinal diseases and nutritional disorders associated with osteoporosis

Česká verzia

Authors: I. Kajaba ¹; A. Krátky ¹; M. Krajčovičová-Kudláčková ¹; K. Fatrcová-Šramková ²; K. Bitter ³; G. Belay ¹
Authors place of work: Slovenská zdravotnícka univerzita v Bratislave ¹; Slovenská poľnohospodárska univerzita v Nitre ²; Špecializovaná nemocnica sv. Svorada Zobor, n. o., Nitra ³
Published in the journal: Gastroent Hepatol 2012; 66(6): 450-457
Category: Clinical and Experimental Gastroenterology: Review Article

Summary

The authors report on the co-morbidity of selected gastrointestinal diseases associated with osteoporosis. The American Gastroenterological Association notes that the basic gastrointestinal diseases which demonstrate relationships with osteoporosis are inflammatory bowel diseases, celiac disease, lactose intolerance, liver osteopathy, conditions after gastrectomy and post-transplant conditions. Progressive immunological views in the ethiopathogenesis of these diseases and also in connection with osteoporosis are pointed out. In conclusion, complex preventive and therapeutic methods are highlighted in secondary osteoporosis, including the key roles nutrition and optimal physical activity take.

Key words:
osteoporosis – inflammatory bowel disease – celiac disease – lactose intolerance – gastrectomy – liver diseases

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
30. 7. 2012

Accepted:
10. 9. 2012

Zdroje

1. Embutnieks IV, Drozdov VN, Chernyshova IV et al. Disorders of bone mineral density in patients with the digestive system diseases. Eksp Klin Gastroenterol 2011; (2): 111–116.

2. Bianchi ML. Inflammatory bowel diseases, celiac disease, and bone. Arch Biochem Biophys 2010; 503(1): 54–65.

3. American Gastroenterologic Association. Osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124(3): 795.

4. Kmečová Z. Sekundárna osteoporóza pri zápalových chorobách čreva. Via Practica 2008; 5: 469–471.

5. Príkazská M. Crohnova choroba – nie výlučne črevné ochorenie. CC Bulletin 2000; 7: 9–10.

6. Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Rheumat Dis 2010; 13(3): 259–265.

7. Kolios G, Petoumenos C, Nakos A. Mediators of inflammation, production and aplication in inflammatory bowel disease. Hepatogastroent 1998; 45(23): 1601–1609.

8. Krátky A. Liečba Crohnovej choroby anti-TNFα (Infliximab). Bratislava: SPAM 2002.

9. Kmečová Z, Rovenský J, Šváč J. Zníženie kostnej denzity u pacientov so zápalovými ochoreniami čreva, aktivita ochorenia a hladina interleukínu 6 a 10. Rheumatologia 2006; 20: 87–92.

10. Kajaba I, Šimončič R, Nagyová A. Úloha minerálií v prevencii a liečbe osteoporózy. Slov Lek 2006; 16: 70–73.

11. Hernandez L, Green PH. Extraintestinal manifestations of celiac disease. Curr Gastroenterol Rep 2006; 8(5): 383–389.

12. Cashman KD. Altered bone metabolism in inflammatory disease, role of nutrition. Proc Nutr Soc 2008; 67(2): 196–205.

13. Thomason K, West J, Logan RFA et al. Fracture experience of patients with celiac disease, a population based survey. Gut 2003; 52(4): 518–522.

14. Capriles VD, Martini LA, Areas JA. Metabolic osteopathy in celiac disease, importance of a gluten-free diet. Nutr Rev 2009; 67(10): 599–606.

15. Gajdoš M. Statíny a kosť. Slovakofarma Rev 2002; 12: 82–85.

16. Masaryk P, Letkovská A, Rovenský J. Stroncium ranelát – unikátny efekt v liečbe osteoporózy. Med Monit 2005; 10: 28–30.

17. Žofková I. Celiakie a její vztah ke kostnímu metabolismu. Čas Lék Čes 2009; 148(6): 246–248.

18. Kocián J. Osteoporóza a osteomalácie. Praha: Triton 1995.

19. Matlik L, Savaiano D, McCabe G et al. Perceived milk intolerance is related to bone mineral content in 10 to 13 years old female adolescents. Pediatrics 2007; 120(3): 669–677.

20. Keith JN, Nicholls J, Reed A et al. The prevalence of self-reported lactose intolerance and the consumption of dairy foods among African American adults are less than expected. J Natl Med Assoc 2011; 103(1): 36–45.

21. Guanabens N, Pares A. Osteoporosis in liver cirrhosis. Gastroenterol Hepatol 2012; 35(6): 411–420.

22. Guanabens N, Pares A. Liver and bone. Arch Biochem Biophys 2010; 503(1): 84–94.

23. Lopez-Larramona G, Lucendo AJ, Gonzalez-Castillo S et al. Hepatic osteodystrophy, an important mater for consideration in chronic liver disease. World J Hepatol 2011; 3(12): 300–307.

24. Monegal A, Navasa M, Guanabens N et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for liver transplantation. Calcif Tissue Int 1997; 60(2): 148–154.

25. Wibaux C, Legroux-Gerot I, Dharancy S et al. Assessing bone status in patients awaiting liver transplantation. Joint Bone Spine 2011; 78(4): 387–391.

26. Lorraine A, Fitzpatrick MD. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77(5): 453–468.

27. Ramsey-Goldmann R, Dunn JE, Dunlop DD et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999; 14(3): 456–463.

28. Katz I, Li M, Joffe I et al. Influence of age on cyklosporin A-induced alterations in bone mineral metabolism in the rat in vivo. J Bone Miner Res 1994; 9(1): 59–67.

29. Liedman B, Bosaeus I, Mellstrom D et al. Osteoporosis after total gastrectomy. Scand J Gastroenterol 1997; 32(11): 1090–1095.

30. Resch H, Pietschmann P, Petnecker B et al. The influence of partial gastrectomy on biochemical parameters of bone metabolism and bone density. Clin Investig 1992; 70(5): 426–429.

31. Lim JS, Jin SH, Kim SB et al. Effect of biphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy. J Clin Gastroenterol 2012; 46(8): 669–674.

32. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 2003; 15(8): 857–864.

33. Sipponen P, Harkonen M. Hypochlorhydric stomach, a risk condition for calcium malabsorption and osteoporosis? Scand J Gastroenterol 2010; 45(2): 133–138.

34. Sudeep K, Chacko A, Thomas N et al. Predictors of osteodystrophy in patients with chronic nonalcoholic pancreatitis with or without diabetes. Endocr Pract 2011; 17(6): 897–905.

35. Herrmann M, Peter Smidt J, Umanskaya N et al. The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis, a systematic review. Clin Chem Lab Med 2007; 45(12): 1621–1632.

36. Roblin X, Phelip JM, Genevois M et al. Hyperhomocysteinemia is associated with osteoporosis in patients with Crohn´s disease. Aliment Pharmacol Ther 2007; 25(7): 797–804.

37. Winston AP, Alwazeer AE, Bankart MJ. Screening for osteoporosis in anorexia nervosa, prevalence and predictors of reduced bone mineral density. Int J Eat Disord 2008; 41(3): 284–287.

38. Baumann KH, Hessel F, Larass I et al. Dietary n-3, n-6 and n-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. Arterioscler Thromb Vasc Biol 1999; 19(1): 59–66.

39. Šimek J. Vliv hlavních živin na tvorbu eikosanoidu – PUFA z řady omega-3 (27–32). In: Výživa a zdraví 99. Teplice: OHS 1999.

40. Gajdoš M, Cibuľová Ľ. Statíny a osteoporóza. Lek Obz 2004; 53(11): 408–411.

41. Meier CR, Schlienger RG, Kraenzlin ME et al. HMG-CoA reductase inhibitors and the risk fractures. JAMA 2000; 283(24): 3205–3210.

42. Pazianas M., Rhim AD, Weinberg AM et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn disease. Ann N Y Acad Sci 2006; 1068: 543–556.